A Church Based Intervention to Improve Diabetes Care

This study has been completed.
Centers for Disease Control and Prevention
Information provided by:
University of North Carolina, Chapel Hill
ClinicalTrials.gov Identifier:
First received: March 31, 2006
Last updated: NA
Last verified: December 2005
History: No changes posted
The purpose of this study it to determine if a culturally appropriate, church based intervention for African Americans with type 2 diabetes, will lead to improved glycemic (blood sugar) control.

Condition Intervention
Type 2 Diabetes
Behavioral: diabetes self care (behavior)

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Church Based Intervention to Improve Diabetes Care

Further study details as provided by University of North Carolina, Chapel Hill:

Primary Outcome Measures:
  • Hemoglobin A1c

Secondary Outcome Measures:
  • Diet (change in saturated fat)
  • Physical Activity

Estimated Enrollment: 280
Study Start Date: February 2001
Estimated Study Completion Date: August 2003
Detailed Description:

African Americans suffer disproportionately from diabetes and its complications. To reduce this burden of suffering, innovative interventions are needed to improve self-care behaviors including: dietary intake, physical activity (PA), self-monitoring, and medication adherence. The goal of this study (A New DAWN) was to develop and test a culturally appropriate, church-based intervention to improve diabetes self-management and glycemic control.

Twenty-four African American churches in central NC were recruited and randomized to receive the special intervention (SI–13 churches, 117 participants) or the delayed intervention (DI–11 churches, 84 participants). The SI included an 8-month intensive phase consisting of: 1 individual dietary assessment and counseling visit; 12 group sessions; monthly phone contact with a peer counselor (church diabetes advisor (CDA)); and 3 printed encouragement messages from the primary care clinician. This was followed by a 4-month reinforcement phase including monthly phone contacts from the CDA. At 8- and 12-month follow-up, HbA1c was assessed by high-performance liquid chromatography.

At baseline, 64% of participants were female and means were: age 59, years with diabetes 9, HbA1c 7.8%, SBP 139, DBP 76, and BMI 35.0. A total of 174 (87%) participants returned for 8-month measures. Adjusting for baseline values and randomization by church, the mean HbA1c level was 7.4% for the SI and 7.8% for the DI (difference 0.4%, 95% CI 0.1-0.6, p = 0.009). There were no statistically significant differences between groups for BP or BMI. Of 82 (70%) SI participants completing an 8-month follow-up questionnaire, 65 (79%) were very satisfied with the nutritional component, 63 (77%) were very satisfied with the PA component, and 72 (88%) considered the program to be very helpful overall.

In A New DAWN, the SI was acceptable and produced a modest, but clinically significant, reduction in HbA1c. These findings support the acceptability and effectiveness of self-management interventions given in a church setting for African Americans with type 2 diabetes.


Ages Eligible for Study:   20 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • age 20 or older
  • diagnosis of type 2 diabetes (diagnosis at age 20 or greater and no history of ketoacidosis)
  • clinical care provided by primary care clinician
  • plans to reside within 50 miles of chuch for 1 year
  • has home phone or easy access to one

Exclusion Criteria:

  • diabetes secondary to another condition
  • pregnancy/lactation
  • inability to speak English
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00311324

United States, North Carolina
Center for Health Promotion and Disease Prevention/UNC-Chapel Hill
Chapel Hill, North Carolina, United States, 27599
Sponsors and Collaborators
University of North Carolina
Centers for Disease Control and Prevention
Principal Investigator: Thomas C. Keyserling, MD, MPH University of North Carolina, Chapel Hill
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00311324     History of Changes
Other Study ID Numbers: Project 99-MED-412, U48/CCU409660
Study First Received: March 31, 2006
Last Updated: March 31, 2006
Health Authority: United States: Institutional Review Board

Keywords provided by University of North Carolina, Chapel Hill:
behvioral intervention

ClinicalTrials.gov processed this record on November 30, 2015